Stock Market Reviews

IART (Integra LifeSciences Holdings Corporation) News

Get the latest news, insights, and market updates on IART (Integra LifeSciences Holdings Corporation). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Integra LifeSciences (IART) Stock Trades Up, Here Is Why
  Shares of medical device company Integra LifeSciences (NASDAQ:IART) jumped 1.7% in the afternoon session after the company received U.S. FDA 510(k) clearance for its CUSA Clarity Ultrasonic Surgical Aspirator System, allowing its use in cardiac surgery.
  Nov 13, 2025 - $IART
• Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA® Clarity Ultrasonic Surgical Aspirator System for Cardiac Surgeries
  CUSA Clarity CUSA Clarity Ultrasonic Surgical Aspirator System PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is pleased to announce the FDA 510(k) clearance for use of its CUSA® Clarity Ultrasonic Surgical Aspirator System for cardiac surgeries. The recent clearance for specific cardiac indications encompasses the debridement of unwanted tissue in cardiac surgeries, including valve replace
  Nov 11, 2025 - $IART
• 3 of Wall Street’s Favorite Stocks We Keep Off Our Radar
  Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
  Nov 10, 2025 - $IART
• Exploring 3 Undervalued Small Caps With Insider Buying Across Regions
  In the current U.S. market landscape, small-cap stocks have faced a challenging environment as broader indices like the S&P 600 reflect investor concerns over economic indicators and ongoing government shutdowns. Despite these headwinds, opportunities may exist for discerning investors who focus on companies with strong fundamentals and insider confidence, as evidenced by recent buying activity.
  Nov 10, 2025 - $IART
• 5 Must-Read Analyst Questions From Integra LifeSciences’s Q3 Earnings Call
  Integra LifeSciences’ third quarter was marked by operational disruptions and underwhelming revenue growth, resulting in a significant negative market reaction. Management attributed the revenue shortfall to two supply interruptions in its Codman Specialty Surgical (CSS) business and insufficient inventory levels, which offset healthy demand across the company’s broader portfolio. CEO Mojdeh Poul noted, “Our third quarter revenue shortfall underscores the work still ahead to achieve greater exec
  Nov 6, 2025 - $IART
• Why Integra LifeSciences (IART) Shares Are Trading Lower Today
  Shares of medical device company Integra LifeSciences (NASDAQ:IART) fell 5.7% in the afternoon session after the stock's negative momentum continued as the company reported weak third-quarter results and analysts lowered their price targets on the stock.
  Nov 3, 2025 - $IART
• Integra LifeSciences (IART): Deep Losses and Discounted Valuation Shape Sentiment Ahead of Earnings
  Integra LifeSciences Holdings (IART) remains unprofitable, with losses accelerating at a 59% per year pace over the last five years. Revenue is forecast to grow just 2.5% annually, trailing the broader US market’s expected 10.3% growth, while net profit margins have failed to improve. Despite these challenges, consensus forecasts see the company turning profitable in the next three years, with earnings anticipated to surge 115.31% per year during that window. See our full analysis for Integra...
  Nov 1, 2025 - $IART
• IART Q3 Deep Dive: Supply Chain Progress, Product Relaunches, and Margin Pressures Shape Outlook
  Medical device company Integra LifeSciences (NASDAQ:IART) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 5.6% year on year to $402.1 million. Next quarter’s revenue guidance of $430 million underwhelmed, coming in 5.9% below analysts’ estimates. Its non-GAAP profit of $0.54 per share was 24.1% above analysts’ consensus estimates.
  Oct 31, 2025 - $IART
• Integra (IART) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
  While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
  Oct 30, 2025 - $IART
• Integra: Q3 Earnings Snapshot
  PRINCETON, N.J. (AP) — Integra LifeSciences Holdings Corp. IART) on Thursday reported a loss of $5.4 million in its third quarter. The Princeton, New Jersey-based company said it had a loss of 7 cents per share.
  Oct 30, 2025 - $IART